Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...

Xie Qing, director of infectious diseases department at Ruijin Hospital, which is affiliated with Shanghai Jiao Tong ...

There are many reasons why tourists consider visiting New Zealand. The island country — located in the southwestern Pacific ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Scientists from the Institut Pasteur, in collaboration with Kumamoto University in Japan, have assessed a new rapid ...

People fully vaccinated against hepatitis B who are not immunocompromised can expect sustained immunity throughout their ...

Minister of State for Health Anupriya Patel clarified that the WHO's data on Indian Hepatitis B and C cases is based on ...

Still, a bout of hepatitis A can last weeks or months, and the worst cases can cause liver damage and even death. Since 1995, ...

Thomas Jeffries does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...